Evidence map›Paper›PMID 26497763›Full record

ArticleScientific reports2015

The protective role of montelukast against intestinal ischemia-reperfusion injury in rats.

Shenbao Wu, Xuxing Zhu, Zhonghai Jin, Xiuping Tong, Liqin Zhu, Xiaofei Hong, Xianfei Zhu, Pengfei Liu, Weidong Shen

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Leukotrienes and kidney diseases.Current opinion in nephrology and hypertension · 2018
    Review
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Shenbao WuDepartment of Gastroenterology, the Affiliated Yiwu Hospital of Wenzhou Medical College, Yiwu 322000, PR China.
Xuxing ZhuDepartment of Gastroenterology, the Affiliated Yiwu Hospital of Wenzhou Medical College, Yiwu 322000, PR China.
Zhonghai JinDepartment of Gastroenterology, the Affiliated Yiwu Hospital of Wenzhou Medical College, Yiwu 322000, PR China.
Xiuping TongDepartment of Gastroenterology, the Affiliated Yiwu Hospital of Wenzhou Medical College, Yiwu 322000, PR China.
Liqin ZhuDepartment of Gastroenterology, the Affiliated Yiwu Hospital of Wenzhou Medical College, Yiwu 322000, PR China.
Xiaofei HongDepartment of Gastroenterology, the Affiliated Yiwu Hospital of Wenzhou Medical College, Yiwu 322000, PR China.
Xianfei ZhuDepartment of Gastroenterology, the Affiliated Yiwu Hospital of Wenzhou Medical College, Yiwu 322000, PR China.
Pengfei LiuDepartment of Gastroenterology, the Affiliated Jiangyin Hospital of Nantong University Medical School, Jiangyin 214400, PR China.
Weidong ShenDepartment of Gastroenterology, the Affiliated Jiangyin Hospital of Nantong University Medical School, Jiangyin 214400, PR China.
Wenzhou Medical University · CNJiangyin People's Hospital · CNNantong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Several drugs are effective in attenuating intestinal ischemia-reperfusion injury (IRI); however little is known about the effect of montelukast. Fifty rats were randomly assigned to 3 groups: model group (operation with clamping), sham group (operation without clamping), and study group (operation with clamping and 0.2, 2 and 20 mg/kg montelukast pretreatment). Intestinal ischemia-reperfusion was performed by occlusion (clamping) of the arteria mesenterica anterior for 45 min, followed by 24 h reperfusion. Intestinal IRI in the model group led to severe damage of the intestinal mucosa, liver and kidney. The Chiu scores of the intestines from the study group (2 and 20 mg/kg) were lower than that of the model group. Intestinal IRI induced a marked increase in CysLTR1, Caspase-8 and -9 expression in intestine, liver and kidney, which were markedly reduced by preconditioning with 2 mg/kg montelukast. Preconditioning with 2 g/kg montelukast significantly attenuated hepatic tissue injury and kidney damage, and decreased plasma interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) levels in plasma after intestinal IRI. In conclusion, preconditioning with montelukast could attenuate intestinal IRI and the subsequent systemic inflammatory response in rats.

Indexed as

AcetatesAcute-Phase ProteinsAlanine TransaminaseAnimalsAspartate AminotransferasesCaspase 8Caspase 9CyclopropanesInterleukin-6Intestinal MucosaKidneyLipocalin-2LipocalinsLiverMaleProtective AgentsAcetatesAcute-Phase ProteinsAlanine TransaminaseAspartate AminotransferasesCaspase 8Caspase 9Cyclopropanescysteinyl leukotriene receptor 2Interleukin-6Lcn2 protein, ratLipocalin-2LipocalinsmontelukastProtective AgentsProto-Oncogene ProteinsQuinolinesReceptors, LeukotrieneRNA, MessengerSulfidesTumor Necrosis Factor-alpha

Identifiers

PMID26497763
PMCPMC4620564
OpenAlexW2402570435

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.